Intended for healthcare professionals

Practice NIHR Alerts

How common are side effects of treatment to prevent gout flares when starting allopurinol?

BMJ 2024; 384 doi: (Published 08 March 2024) Cite this as: BMJ 2024;384:q514
  1. Helen Saul, editor in chief1,
  2. Brendan Deeney, science writer1,
  3. Laura Swaithes, knowledge mobilisation research fellow1,
  4. Edward Roddy, professor of rheumatology and honorary consultant rheumatologist2
  1. 1NIHR Evidence, Twickenham, UK
  2. 2Keele University, Keele
  1. Correspondence to H Saul evidence{at}

The study

Roddy E, Bajpai R, Forrester H, et al. Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. Ann Rheum Dis 2023;82:1618-25.

To read the full NIHR Alert, go to:


  • Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.

  • Further details of The BMJ policy on financial interests are here:

  • All authors contributed to the development and review of this summary, as part of the wider NIHR Alerts editorial team.

  • More summaries of NIHR research are available at:

  • Disclaimer: NIHR Alerts are owned by the Department of Health and Social Care and are made available to The BMJ under licence. NIHR Alerts report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Alerts.

  • Permission to reuse these articles should be directed to

View Full Text

Log in

Log in through your institution


* For online subscription